Notwithstanding the significant decline in healthtech valuations in India over recent years, the market has now stabilized with surviving companies being fairly valued, according to Biju Mohandas, Partner and Global Head of Healthcare Investments at LeapFrog Investments, a global impact fund backed by Singapore’s Temasek.
End the Year with a Deal You Can’t Miss!
Subscribe now and save 40% on our premium subscription.
Enjoy unlimited access for a full year at just $199 (usual price $339).
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Offer valid for a limited time – don’t wait to unlock the insights that drive deal-making in Asia!
Subscribe nowAlready a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
